MapLight Therapeutics prices IPO at $17/sh, raises $296.3M including concurrent private placement

MapLight Therapeutics, Inc.

IPO of 14.75M shares at $17.00; underwriters fully exercise option for 2.2125M additional shares.
Concurrent private placement to Goldman Sachs affiliates of 467,707 shares at same $17 price.
Total gross proceeds of $296.3M before underwriting discounts, placement agent fees, and expenses.
Amended and restated certificate of incorporation and bylaws effective upon IPO closing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

MapLight Therapeutics, Inc.: Amended and restated certificate of incorporation filed in connection with IPO closing (effective 2025-10-28).

Change: charter amendment
Effective: 2025-10-28

Exact text from the filing

In connection with the closing of the initial public offering (“ IPO ”) of shares of common stock, par value $0.0001 per share (“ Common Stock ”), of MapLight Therapeutics, Inc. (the “ Company ”), on October 28, 2025, the Company filed an amended and restated certificate of incorporation (the “ Restated Certificate ”) with the Secretary of State of the State of Delaware.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

MapLight Therapeutics, Inc.: Amended and restated bylaws adopted effective upon IPO closing (effective 2025-10-28).

Change: bylaw amendment
Effective: 2025-10-28

Exact text from the filing

Effective as of October 28, 2025, the Company adopted amended and restated bylaws (the “ Restated Bylaws ”) in connection with the closing of the IPO.

View on SEC.gov

261 governance changes filed in the last 30 days. Browse all governance changes →

MapLight Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-255041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.